R&D Products

Human CD8-positive cells

Commercial Designation:Human CD8-positive cells

Catalog Number:LV-CD8+T001

Specifications:1/5million cells per vial

Strain:Southeast Asian populations 

Number of Donors:Single Donor or Multiple Donors

Lead Time: 1 week 

Storage Conditions:Strict liquid nitrogen storage with continuous temperature monitoring, as repeated temperature fluctuations during cryocontainer handling may compromise cell viability post-thawing.

Transport Conditions:Liquid Nitrogen Transportation 

Shelf Life:10 years

Quality Control (QC) Parameters :Thawing recovery data (viability; viable cell count; contamination detection)、Cell FACS Analysis (Anti-CD4 Antibody and Other Markers)、Suspension Effect.

Information
Cultivation steps
Freezing treatment
After sales regulations

 Transport Mode

Liquid Nitrogen Transportation 

1、Adsorptive Liquid Nitrogen Transportation ,No free liquid nitrogen ,White vapor emission indicates normal operation.

2、Temperature monitoring devices should closely monitor the temperature inside the tank during transportation. If any abnormalities are detected, you can copy the PDF and Excel data from the temperature recorder. (One end of the temperature monitoring device can be unplugged to reveal a USB connector. Simply insert it into a computer to copy the data. If you encounter any difficulties, you can contact the sales staff and technical support for assistance.)

3、Alloy Combination Lock Designed to ensure no third-party access to the LN₂ tank or cell samples during transportation from dispatch to receipt, thereby safeguarding cell integrity.

4、GPS Tracker Enables real-time tracking of cell transportation routes to prevent loss.

5、Liquid Nitrogen Tank, temperature monitoring device, alloy combination lock, and GPS tracker are returnable components. Please store them properly and avoid damage; failure to comply will result in blacklisting.


Reference Citation

blush.


Scope of Application

The research applications of human CD8⁺ T cells can be summarized as the following core directions:

1.Cancer Immunotherapy Development

CAR-T Cell Therapy: CD8+ T cells are engineered to target tumor-associated antigens (e.g., CD19, B-cell maturation antigen/BCMA) for the treatment of hematological malignancies and solid tumors.

Immune checkpoint research: Elucidating the inhibitory mechanisms of PD-1/CTLA-4 to optimize the clinical response of drugs such as anti-PD-1 monoclonal antibodies.

Tumor microenvironment regulation: Investigating CD8⁺ T cell exhaustion markers (such as TIM-3 and LAG-3) to explore combination therapy strategies.

2. Anti-infective Immunity Research

Virus-specific responses: Analyzing CD8⁺ T cell escape mechanisms during HIV and HCV infections to design TCR-T cell therapies or vaccines.

Vaccine efficacy assessment: Evaluating the magnitude of vaccine-induced CD8⁺ T cell responses via IFN-γ ELISpot assay.

3. Autoimmune Diseases and Immunoregulation

Regulatory CD8+ T Cells: Identifying Subsets Suppressing Autoreactive T Cells (e.g., CD8+ Treg) for Therapeutic Exploration in Multiple Sclerosis and Type 1 Diabetes

Inflammatory Balance Mechanisms: Investigating the Pro-inflammatory and Anti-inflammatory Dual Roles of CD8+ T Cells in Chronic Inflammation (e.g., Rheumatoid Arthritis).

4. Immunosenescence and Chronic Diseases

Analysis of Senescence Markers: Investigating the Association Between Telomere Shortening, Loss of CD28 Expression, and Age-Related Decline in Immune Function.

Metabolic Disease Pathogenesis: Elucidating the Pathogenic Mechanisms of CD8+ T Cell Infiltration in Adipose Tissue during Obesity or Diabetes.

5. Emerging Technologies and Translational Medicine

Single-Cell Omics: Deciphering CD8+ T Cell Clonal Expansion and Heterogeneity in Tumor and Infection Contexts (e.g., Tissue-Resident Memory TRM Cells) .

TCR Sequencing: Screening High-Affinity TCRs for Personalized Immunotherapy.

Conclusion

Research on Human CD8+ T Cells: Focusing on Cancer Immunotherapy, Anti-Pathogen Defense, Autoimmune Regulation, and Senescence Mechanisms. Integrated with Gene Editing and Omics Technologies to Drive Clinical Translation of Precision Immunotherapies.

由于我司产品说明书半年更新一次,以下步骤仅作参考,以公司随货说明书为准

 

试剂与材料

Ø 冻存CD4阳性T细胞Cat# LV-CD4+T001/2

Ø 培养基(完全RPMI1640培养基,见下表)

Ø 37℃恒温水浴锅

Ø 生物安全柜

Ø 15ml离心管

Ø 37℃/5% CO2培养箱

Ø 宽口滴管和宽口移液枪头

Ø 移液枪

Ø 75%酒精


II 完全RPMI1640培养基

成分

用量

不完全RPMI1640溶液

500ml

左旋谷氨酰胺(L-Glu

2mM

2-巯基乙醇(2-ME

50μM

青霉素(Penicillin)

100U/ml

链霉素(Streptomycin)

100μg/ml

FCS(56℃灭活30min)

50ml

特别提醒:复苏培养基中补加300mM葡萄糖,可提升细胞活力及活细胞数。


III 细胞的复苏与铺板

重要提示:解冻时,冻存细胞转移必须使用液氮转移;在整个复苏实验过程中必须全程使用宽口枪头。

1. 完全RPMI1640培养基放入37℃恒温水浴锅中让其充分预热。

2. 将冻存的细胞从冷藏位置迅速转移至37℃恒温水浴锅中。将冻存管尽可能多的浸入37℃水中,作规律的水平摇动,但必须确保冻存管盖子保持在水面以上。

3. 解冻冻存管至刚好完全溶解成液体,约90-120秒。

4. 75%酒精对冻存管消毒,并将其转移到生物安全

5. 小心地将解冻后的细胞吸出,移至15ml离心管,并

用培养基润洗一遍冻存管及吸取细胞的枪头。

6. 一边摇晃离心管,一边加入完全RPMI1640培养基至12ml(注意:前3ml要缓慢逐滴加入并摇晃,后面9ml可加快速度),最后上下颠倒混匀。

7. 20℃500g,升速7,降速4,离心8min

8. 弃上清,加入3ml完全RPMI1640培养基重悬细胞,并用台盼蓝染色计数V细胞悬液V0.4%台盼蓝=91细胞活率使用血球计数板手工计数,勿用细胞计数仪;细胞总数使用细胞计数仪计数测定细胞的活力、细胞建议细胞总数检测3次,求取平均值;为节约时间,细胞活率检测1

9. 实验要求的密度进行铺板

10. 37/ 5% CO2培养箱中培养。

Cells should not be re-cryopreserved after thawing.

VI Regarding After-Sales Service

      Quality Assurance & After-Sales Policy In the event of product quality issues, please: Collect original data Contact our sales representatives or technical support team immediately We will dispatch personnel to address the issue promptly.

      After-Sales Validity Period & Submitted Original Data:

      Resuscitation issues: Report any abnormalities immediately and provide results of Trypan blue staining or AO/PI staining.

      Contamination issues: Report within 96 hours after resuscitation and provide phase-contrast microscope photos.

      Purity issues: Report within one month of detection and provide immunofluorescence or flow cytometry results.


VII  Contact Number

      Company Telephone:0755-28284050

      Technical Support:19902901483( Dr. Zhou



Cell Culture Guidelines